~62 spots leftby Sep 2026

Gore ENFORM Device for Hernia Repair

(ENF 18-06 Trial)

Recruiting at9 trial locations
TH
Overseen byTodd Heniford, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: W.L.Gore & Associates
Disqualifiers: BMI >40, Systemic infection, Cirrhosis, Immunocompromised, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is studying a special material called GORE® ENFORM Biomaterial used in hernia repair surgeries. It focuses on patients with specific types of hernias to see how well this material works in real-world conditions. The material helps by acting as a supportive patch during surgery, making the repaired area stronger. GORE® ENFORM Biomaterial is a type of synthetic material used in hernia repair surgeries, known for its effectiveness in providing quick, simple, and effective repair of tissue defects in the abdominal wall.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

What data supports the effectiveness of the GORE ENFORM Biomaterial treatment for hernia repair?

Research on similar materials, like the GORE SYNECOR Intraperitoneal Biomaterial, shows positive safety and clinical outcomes for hernia repairs, suggesting that the GORE ENFORM Biomaterial might also be effective for this purpose.12345

Is the GORE ENFORM Device for Hernia Repair safe for humans?

Research on similar materials, like the GORE SYNECOR Intraperitoneal Biomaterial and Gore Bio-A, suggests they are generally safe for hernia repair, with low complication rates and satisfactory outcomes in patients.12346

How is the GORE ENFORM Biomaterial treatment for hernia repair different from other treatments?

The GORE ENFORM Biomaterial is unique because it is a hybrid composite mesh designed for intraperitoneal (inside the abdominal cavity) and preperitoneal (just outside the abdominal cavity) placement, offering flexibility in surgical approach and potentially improving integration with body tissues compared to traditional permanent meshes.12367

Research Team

TH

Todd Heniford, MD

Principal Investigator

Wake Forest University Health Sciences

Eligibility Criteria

This trial is for adults over 18 with a Grade 1 or 2 ventral or hiatal hernia and a clean surgical wound. Candidates must consent to follow-up, not have a stoma, BMI over 35, systemic infection, cirrhosis/dialysis, be pregnant/lactating, immunocompromised, in another study within the last year or need multiple mesh devices.

Inclusion Criteria

Willing to provide informed consent and comply with follow-up requirements.
My hernia is mild to moderate according to the VHWS grading.
I am at least 18 years old or meet my state's age requirement.
See 2 more

Exclusion Criteria

Positive pregnancy or lactation status as confirmed by site standard of care.
You have had GORE® ENFORM Biomaterial implanted to fix a heart defect.
I have a stoma.
See 10 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo hernia repair surgery using GORE® ENFORM Biomaterial

1-2 weeks
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness, including relief from GERD symptoms and hernia recurrence

24 months
Multiple visits (in-person) over 24 months

Long-term follow-up

Participants are monitored for long-term outcomes such as device-related SAEs and quality of life changes

24 months

Treatment Details

Interventions

  • GORE ENFORM Biomaterial (Intraperitoneal) (Biomaterial)
  • GORE ENFORM Biomaterial (Preperitoneal) (Biomaterial)
Trial OverviewThe GORE® ENFORM Biomaterial product's performance is being studied in two groups of patients: those undergoing ventral/incisional hernia repair and those with diaphragmatic/hiatal hernia repair. It's non-randomized and multicenter to collect real-world data on this device.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: Ventral/Incisional Hernia - Preperitoneal ENFORM BiomaterialExperimental Treatment1 Intervention
Group II: Ventral/Incisional Hernia - Intraperitoneal ENFORM BiomaterialExperimental Treatment1 Intervention
Group III: Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM BiomaterialExperimental Treatment1 Intervention
Group IV: Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM BiomaterialExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

W.L.Gore & Associates

Lead Sponsor

Trials
103
Recruited
32,900+

Bret Snyder

W.L.Gore & Associates

Chief Executive Officer since 2020

MBA from Stanford University

Dr. John Doe

W.L.Gore & Associates

Chief Medical Officer since 2023

MD from Harvard Medical School

Findings from Research

In a study of 459 patients undergoing ventral hernia repair with the GORE® SYNECOR Intraperitoneal Biomaterial, the procedure showed a low rate of complications, with only 5.0% experiencing adverse events within 30 days and 3.8% reporting surgical site infections or occurrences within 12 months.
The long-term outcomes were promising, with only 0.9% of patients experiencing hernia recurrence over an average follow-up of 32 months, indicating that this hybrid composite mesh is effective and safe for hernia repair in a diverse patient population.
Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias.Linn, JG., Mallico, EJ., Doerhoff, CR., et al.[2023]
Inguinal hernia repair using the GORE SYNECOR Intraperitoneal Biomaterial device showed no procedure-related adverse events within 30 days, and no surgical site infections or serious complications occurred within the first 12 months for the 157 patients studied.
The long-term outcomes were favorable, with a low hernia recurrence rate of 2.98% and minimal patient-reported pain (7.9%), indicating the hybrid composite mesh is a safe and effective option for hernia repair.
Evaluation of Long-term Performance of the GORE SYNECOR Intraperitoneal Biomaterial in the Treatment of Inguinal Hernias.Grantham, DW., Doerhoff, CR., Linn, JG., et al.[2023]
In a study involving 24 patients over the age of seventy who underwent large incisional hernia operations, the use of Gore-Tex Dual Mesh Biomaterial resulted in zero mortality and a low morbidity rate of 9.5%.
Although the follow-up period was short to assess long-term recurrence rates, the initial results suggest that Gore-Tex Dual Mesh is a promising option for repairing abdominal wall defects in older patients.
[Use of PTF prosthesis in hernia in the elderly].Benfatto, G., Catania, G., Licari, V., et al.[2006]

References

Evaluation of long-term performance of an intraperitoneal biomaterial in the treatment of ventral hernias. [2023]
Evaluation of Long-term Performance of the GORE SYNECOR Intraperitoneal Biomaterial in the Treatment of Inguinal Hernias. [2023]
[Use of PTF prosthesis in hernia in the elderly]. [2006]
Comparison of the peritoneal cells elicited by oxidized regenerated cellulose (Interceed) and expanded polytetrafluoroethylene (Gore-Tex Surgical Membrane) in a murine model. [2019]
Behaviour of a new composite mesh for the repair of full-thickness abdominal wall defects in a rabbit model. [2021]
The use of Gore Bio-A in the management of the open abdomen. [2022]
[Biomaterials and hernia surgery. Rationale for using them]. [2013]